Dermata Net Income Per Share from 2010 to 2026
| DRMA Stock | USD 1.83 0.06 3.39% |
Net Loss | First Reported 2010-12-31 | Previous Quarter (72.28) | Current Value (75.89) | Quarterly Volatility 588.65912188 |
Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 272.6 K, Depreciation And Amortization of 15.1 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.13. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.
Dermata | Net Income Per Share | Build AI portfolio with Dermata Stock |
Analyzing Dermata Therapeutics's Net Income Per Share over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Per Share has evolved provides context for assessing Dermata Therapeutics's current valuation and future prospects.
Latest Dermata Therapeutics' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Dermata Therapeutics over the last few years. It is Dermata Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend |
|
Net Income Per Share |
| Timeline |
Dermata Net Income Per Share Regression Statistics
| Arithmetic Mean | (909.42) | |
| Coefficient Of Variation | (64.73) | |
| Mean Deviation | 533.56 | |
| Median | (1,361) | |
| Standard Deviation | 588.66 | |
| Sample Variance | 346,520 | |
| Range | 1.3K | |
| R-Value | 0.86 | |
| Mean Square Error | 93,065 | |
| R-Squared | 0.75 | |
| Slope | 100.83 | |
| Total Sum of Squares | 5.5M |
Dermata Net Income Per Share History
About Dermata Therapeutics Financial Statements
Dermata Therapeutics stakeholders use historical fundamental indicators, such as Dermata Therapeutics' Net Income Per Share, to determine how well the company is positioned to perform in the future. Although Dermata Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Dermata Therapeutics' assets and liabilities are reflected in the revenues and expenses on Dermata Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | (72.28) | (75.89) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out the analysis of Dermata Therapeutics Correlation against competitors. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.